PMID- 29953528
OWN - NLM
STAT- MEDLINE
DCOM- 20181219
LR  - 20240327
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 6
DP  - 2018
TI  - Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients 
      under the anticoagulant treatment.
PG  - e0199900
LID - 10.1371/journal.pone.0199900 [doi]
LID - e0199900
AB  - BACKGROUND: Heparin therapy and prophylaxis may be accompanied by bleeding and 
      thrombotic complications due to individual responses to treatment. Dosage control 
      based on standard laboratory assays poorly reflects the effect of the therapy. 
      The aim of our work was to compare the heparin sensitivity of new thrombodynamics 
      (TD) assay with sensitivity of other standard and global coagulation tests 
      available to date. STUDY POPULATION AND METHODS: A total of 296 patients with 
      high risk of venous thromboembolism (deep vein thrombosis (DVT), early 
      postoperative period, hemoblastosis) were enrolled in the study. We used a 
      case-crossover design to evaluate the sensitivity of new thrombodynamics assay 
      (TD) to the hemostatic state before and after unfractionated heparin (UFH) and 
      low-molecular-weight heparin (LMWH) therapy/prophylaxis and to compare it with 
      the activated partial thromboplastin time (APTT), anti-Xa activity test, thrombin 
      generation test (TGT) and thromboelastography (TEG). A receiver operating 
      characteristic (ROC) curve analysis was used to evaluate changes before and after 
      heparin prophylaxis and therapy. Blood was sampled before heparin injection, at 
      the time of maximal blood heparin concentration and before the next injection. 
      RESULTS: Hypercoagulation before the start of heparin treatment was detected by 
      TD, TGT and TEG but not by APTT. The area under the ROC curve (AUC) was maximal 
      for TD and anti-Xa, intermediate for TGT and TEG and minimal for APTT. 
      CONCLUSIONS: These results indicate that TD has a high sensitivity to the effects 
      of UFH and LMWH after both prophylactic and therapeutic regimes and may be used 
      for heparin monitoring.
FAU - Balandina, Anna N
AU  - Balandina AN
AD  - Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and 
      Immunology, Moscow, Russia.
AD  - Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia.
FAU - Serebriyskiy, Ilya I
AU  - Serebriyskiy II
AD  - Russian Laboratory Federation, Moscow, Russia.
FAU - Poletaev, Alexander V
AU  - Poletaev AV
AD  - Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and 
      Immunology, Moscow, Russia.
FAU - Polokhov, Dmitry M
AU  - Polokhov DM
AD  - Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and 
      Immunology, Moscow, Russia.
FAU - Gracheva, Marina A
AU  - Gracheva MA
AD  - Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and 
      Immunology, Moscow, Russia.
FAU - Koltsova, Ekaterina M
AU  - Koltsova EM
AUID- ORCID: 0000-0003-0167-6726
AD  - Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and 
      Immunology, Moscow, Russia.
AD  - Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia.
FAU - Vardanyan, David M
AU  - Vardanyan DM
AD  - City Clinical Hospital No. 15, Moscow, Russia.
FAU - Taranenko, Irina A
AU  - Taranenko IA
AD  - Altay Regional Clinical Hospital, Barnaul, Russia.
FAU - Krylov, Alexey Yu
AU  - Krylov AY
AD  - Federal State Autonomous Educational Institution of Higher Education I.M. 
      Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Urnova, Evdokiya S
AU  - Urnova ES
AD  - National Research Center for Hematology, Moscow, Russia.
FAU - Lobastov, Kirill V
AU  - Lobastov KV
AUID- ORCID: 0000-0002-5358-7218
AD  - City Clinical Hospital No. 24, Moscow, Russia.
FAU - Chernyakov, Artem V
AU  - Chernyakov AV
AD  - City Clinical Hospital No. 15, Moscow, Russia.
FAU - Shulutko, Elena M
AU  - Shulutko EM
AD  - National Research Center for Hematology, Moscow, Russia.
FAU - Momot, Andrey P
AU  - Momot AP
AD  - National Research Center for Hematology, Altay Department, Barnaul, Russia.
FAU - Shulutko, Alexander M
AU  - Shulutko AM
AD  - Federal State Autonomous Educational Institution of Higher Education I.M. 
      Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Ataullakhanov, Fazoil I
AU  - Ataullakhanov FI
AD  - Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and 
      Immunology, Moscow, Russia.
AD  - Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia.
AD  - Moscow State University, Moscow, Russia.
AD  - Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180628
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Anticoagulants/administration & dosage/pharmacokinetics
MH  - Cross-Sectional Studies
MH  - Drug Monitoring/*methods
MH  - Female
MH  - *Heparin/administration & dosage/pharmacokinetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Thrombelastography
MH  - Venous Thrombosis/blood/*prevention & control
PMC - PMC6023127
COIS- We disclose a conflict of interest for Prof. Fazoil Ataullakhanov, who is a 
      co-founder of HemaCore LLC, which holds several patents and patent applications 
      that are related to the diagnostic use of spatial clot growth and which has 
      developed the assay under the trade name of Thrombodynamics(R) (Ataullakhanov FI, 
      international patent applications PCT/CH2007/000543 filing date 02.11.2007 and 
      capital ER, Cyrilliccapital ES, Cyrilliccapital TE, Cyrillic/RU2012/000570 filing date 16.07.2012). This does not alter our adherence to 
      PLOS ONE policies on sharing data and materials.
EDAT- 2018/06/29 06:00
MHDA- 2018/12/20 06:00
PMCR- 2018/06/28
CRDT- 2018/06/29 06:00
PHST- 2018/03/21 00:00 [received]
PHST- 2018/06/17 00:00 [accepted]
PHST- 2018/06/29 06:00 [entrez]
PHST- 2018/06/29 06:00 [pubmed]
PHST- 2018/12/20 06:00 [medline]
PHST- 2018/06/28 00:00 [pmc-release]
AID - PONE-D-18-08630 [pii]
AID - 10.1371/journal.pone.0199900 [doi]
PST - epublish
SO  - PLoS One. 2018 Jun 28;13(6):e0199900. doi: 10.1371/journal.pone.0199900. 
      eCollection 2018.